sales@fnfresearch.comTel: +91 96043 17127 | USA: 1 (347) 690-0211

Search Market Research Report

Home / Category / Healthcare / B-Cell Maturation Antigen (BCMA) Targeted Therapies

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market by Product Type (CAR-T cell, Antibody Drug Conjugates and Bispecific Antibodies), by Indication (Multiple Myeloma and Acute Lymphoblastic Leukemia) By End User (Hospitals and Cancer Research Institute) By Region : Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026

  • Publish On: Apr-2021
  • Total Pages: 184
  • Report Code: FAF-1455
  • Base Year: 2020
  • Format:

Industry Insights

[184+ Pages Report] According to Facts and Factors, the global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market was measured at around USD 5,150.4 million in 2020, and is forecast to produce sales of around USD 16,487.4 million by the end of 2026, expanding at a CAGR of around 21.4 percent between 2021 and 2026.

Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Overview          

B cell maturation antigen is the target antigen for new MM immunotherapy and plays a role in MM pathophysiology. After dealing with B cell maturation antigen antibody-drug conjugates (ADC), bi-specific T cell engagers and chimeric antigen receptor T, complete responses have been reported in heavily pretreated MM patients. These and further new BCMA-targeted therapies are revolutionizing MM care and patient outcomes.

The CAR T-cell method has been active in some leukemias and lymphomas as a plan to manipulate native antibody or T-cell recognition as well as signaling pathways; the institution of specific genes through viral vectors permits tumor cells to be recognized, resulting in intense post-infusion CAR T-cell expansion and real tumor cell killing. Multiple B-Cell Maturation Antigen -directed CAR T-cell studies have now been conducted around the world, mainly in the USA and China, with similar results of major, rapid activity and huge rates of response-related toxicities such as cytokine release syndrome and neurotoxicity. 14 – 17 One study found that tumor cells expressing as few as 222 BCMA molecules per cell were recognized by the CAR T-cell therapy bb2121, indicating that very low-level BCMA expression appears to be sufficient to activate the killing activity.

Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Growth Factors

When exposed to chemicals or radiations, middle-aged men with a history of monoclonal gammopathy are at the greatest risk of developing multiple myeloma. To provide significant restraints on future growth in the BCMA targeted treatment market, it is critical to raise awareness about the successful treatment of cancer and related diseases among the research community. The global increase in the prevalence of multiple myeloma is projected to fuel the demand for BCMA targeted therapies shortly. Multiple myeloma is cancer that can be terminal and can recur, causing other severe complications. The global prevalence of multiple myeloma and other severe fatal diseases necessitates specific diagnosis and treatment. As a result, there is an urgent need for successful therapies and medical services, which is likely to accelerate the BCMA market's growth in the near future.

Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Segmentation

The global B-Cell Maturation Antigen (BCMA) targeted therapies market is segregated based on product type, indication and end-users, and region

The B-Cell Maturation Antigen (BCMA) targeted therapies market can be divided into three types of products: CAR-T cells, antibody drug conjugates and specific antibodies. These are the numerous types of B-cell maturation antigen products based on the mechanism or function they perform with other proteins or cells in the body, such as , lysis of malignant multiple myeloma, tumor cell identification and destruction, and antibody conjugate formation. Multiple myeloma and acute lymphoblastic leukemia are the indication segment in global B-Cell Maturation Antigen (BCMA) targeted therapies market. Cancer research institutes and hospitals are the end-user segments of the global B-Cell Maturation Antigen (BCMA) targeted therapies market.

Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Regional Analysis

North America is the world's largest market for B-Cell Maturation Antigen (BCMA) targeted therapies market owing to the presence of noticeable market participants coupled with ongoing investment in research and development. Asia Pacific is expected to be the fastest-growing regional market for B-Cell Maturation Antigen (BCMA) targeted therapies market. The second-largest market for B-Cell Maturation Antigen (BCMA) targeted therapies in Europe. Demand is expected to be fuelled shortly by developed nations such as Germany, France, and Italy, among others.

Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Competitive Players

Some main participants of the global B-Cell Maturation Antigen (BCMA) targeted therapies market are Sutro Biopharma, Onyx Pharmaceuticals, GlaxoSmithKline plc, Novartis AG, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Autolus Ltd., Juno Therapeutics, Malin Corporation, Eureka Therapeutics, Transposagen Biopharmaceuticals, Poseida Therapeutics, Inc., firstVentury Equity, Five Prime Therapeutics, Bluebird Bio, Dana-Farber Cancer Institute, Deerfield Partners, and Celgene Corporation others.

By Product Type:

  • CAR-T Cell
  • Antibody Drug Conjugates
  • Bispecific Antibodies

By Indication:

  • Multiple Myeloma
  • Acute Lymphoblastic Leukemia

By End User:

  • Hospitals
  • Cancer Research Institute

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Regional Segment Analysis

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of MEA

KEY REPORT POINTERS & HIGHLIGHTS:

  • Statistically Validated Analysis of Historical, Current, and Projected Industry Trends with Authenticated Market Sizes Information and Data in terms of Value and Volume, wherever applicable
  • Direct and Indirect Factors that Impacted the Industry as well Projected Rationales expected to affect the industry going forward
  • Micro, Meso, Macro, and In-Depth Analysis of Technically relevant and Commercially viable  Segments and Sub-segments of the Market
  • Historical and Projected Company / Vendor / OEM / Supplier Market Shares, Competitive Landscape, and Player Positioning Data
  • Historical and Current Demand (Consumption) and Supply (Production) Scenarios as well as Projected Supply-Demand Scenario Analysis
  • Detailed List of Key Buyers and End-Users (Consumers) analyzed as per Regions and Applications
  • Value Chain and Supply Chain Analysis along with Horizontal and Vertical Integration Scenarios
  • Manufacturing and Production Cost Structure Analysis including Labor Cost, Raw Material Expenses, and Other Manufacturing Expenses, wherever relevant
  • Overview of Key Marketing Strategies and Key Sales Channels Adopted in the Market
  • Market Attractiveness Analysis and Key Investment Opportunity Analysis in the Market going forward
  • Technological Roadmap, Patents Analysis, Potential Substitutes, and Technical Analysis
  • The professionally substantiated market research report study is calculated, constructed, and assembled by implementing a Robust Research Methodology. The Triangular Process comprises a buoyant mix of Exhaustive Primary Research (focused interviews, questionnaires, and ad-hoc surveys) and Extended Secondary Research (paid external databases, proprietary in-house database, and publically-available validated sources), where it is finally triangulated and validated through in-house industry experts, industry leaders, and independent consultants through a tri-level quality check practice.

Table of Content

  1. Chapter 1 Executive Summary
    1. 1.1. Introduction of B-Cell Maturation Antigen (BCMA) Targeted Therapies
    2. 1.2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2020 & 2026 (USD Million)
    3. 1.3. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
    4. 1.4. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Absolute Revenue Opportunity, 2016 – 2026 (USD Million)
    5. 1.5. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Incremental Revenue Opportunity, 2020 – 2026 (USD Million)
    6. 1.6. COVID-19 Impacts on BCMA Targeted Therapies Market
      1. 1.6.1. COVID-19 Impact on the Players
      2. 1.6.2. Business Strategies and Recommendations
  2. Chapter 2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market – Product Type Analysis
    1. 2.1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market – Product Type Overview
    2. 2.2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share, by Product Type, 2020 & 2026 (USD Million)
    3. 2.3. CAR-T Cell
      1. 2.3.1. Global CAR-T Cell B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
    4. 2.4. Antibody Drug Conjugates
      1. 2.4.1. Global Antibody Drug Conjugates B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
    5. 2.5. Bispecific Antibodies
      1. 2.5.1. Global Bispecific Antibodies B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
  3. Chapter 3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market – Indication Analysis
    1. 3.1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market – Indication Overview
    2. 3.2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share, by Indication, 2020 & 2026 (USD Million)
    3. 3.3. Multiple Myeloma
      1. 3.3.1. Global Multiple Myeloma B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
    4. 3.4. Acute Lymphoblastic Leukemia
      1. 3.4.1. Global Acute Lymphoblastic Leukemia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
  4. Chapter 4 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market – End User Analysis
    1. 4.1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market – End User Overview
    2. 4.2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share, by End User, 2020 & 2026 (USD Million)
    3. 4.3. Hospitals
      1. 4.3.1. Global Hospitals B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
    4. 4.4. Cancer Research Institute
      1. 4.4.1. Global Cancer Research Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
  5. Chapter 5 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market – Regional Analysis
    1. 5.1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Regional Overview
    2. 5.2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share, by Region, 2020 & 2026 (USD Million)
    3. 5.3. North America
      1. 5.3.1. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
        1. 5.3.1.1. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Country, 2016 - 2026 (USD Million)
      2. 5.3.2. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type, 2016 – 2026
        1. 5.3.2.1. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type, 2016 – 2026 (USD Million)
      3. 5.3.3. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Indication, 2016 – 2026
        1. 5.3.3.1. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Indication, 2016 – 2026 (USD Million)
      4. 5.3.4. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by End User, 2016 – 2026
        1. 5.3.4.1. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by End User, 2016 – 2026 (USD Million)
      5. 5.3.5. U.S.
        1. 5.3.5.1. U.S. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      6. 5.3.6. Canada
        1. 5.3.6.1. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
    4. 5.4. Europe
      1. 5.4.1. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
        1. 5.4.1.1. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Country, 2016 - 2026 (USD Million)
      2. 5.4.2. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type, 2016 – 2026
        1. 5.4.2.1. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type, 2016 – 2026 (USD Million)
      3. 5.4.3. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Indication, 2016 – 2026
        1. 5.4.3.1. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Indication, 2016 – 2026 (USD Million)
      4. 5.4.4. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by End User, 2016 – 2026
        1. 5.4.4.1. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by End User, 2016 – 2026 (USD Million)
      5. 5.4.5. Germany
        1. 5.4.5.1. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      6. 5.4.6. France
        1. 5.4.6.1. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      7. 5.4.7. U.K.
        1. 5.4.7.1. U.K. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      8. 5.4.8. Italy
        1. 5.4.8.1. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      9. 5.4.9. Spain
        1. 5.4.9.1. Spain B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      10. 5.4.10. Rest of Europe
        1. 5.4.10.1. Rest of Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
    5. 5.5. Asia Pacific
      1. 5.5.1. Asia Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
        1. 5.5.1.1. Asia Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Country, 2016 - 2026 (USD Million)
      2. 5.5.2. Asia Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type, 2016 – 2026
        1. 5.5.2.1. Asia Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type, 2016 – 2026 (USD Million)
      3. 5.5.3. Asia Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Indication, 2016 – 2026
        1. 5.5.3.1. Asia Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Indication, 2016 – 2026 (USD Million)
      4. 5.5.4. Asia Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by End User, 2016 – 2026
        1. 5.5.4.1. Asia Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by End User, 2016 – 2026 (USD Million)
      5. 5.5.5. China
        1. 5.5.5.1. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      6. 5.5.6. Japan
        1. 5.5.6.1. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      7. 5.5.7. India
        1. 5.5.7.1. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      8. 5.5.8. South Korea
        1. 5.5.8.1. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      9. 5.5.9. South-East Asia
        1. 5.5.9.1. South-East Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      10. 5.5.10. Rest of Asia Pacific
        1. 5.5.10.1. Rest of Asia Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
    6. 5.6. Latin America
      1. 5.6.1. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
        1. 5.6.1.1. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Country, 2016 - 2026 (USD Million)
      2. 5.6.2. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type, 2016 – 2026
        1. 5.6.2.1. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type, 2016 – 2026 (USD Million)
      3. 5.6.3. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Indication, 2016 – 2026
        1. 5.6.3.1. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Indication, 2016 – 2026 (USD Million)
      4. 5.6.4. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by End User, 2016 – 2026
        1. 5.6.4.1. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by End User, 2016 – 2026 (USD Million)
      5. 5.6.5. Brazil
        1. 5.6.5.1. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      6. 5.6.6. Mexico
        1. 5.6.6.1. Mexico B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      7. 5.6.7. Rest of Latin America
        1. 5.6.7.1. Rest of Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
    7. 5.7. The Middle-East and Africa
      1. 5.7.1. The Middle-East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
        1. 5.7.1.1. The Middle-East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Country, 2016 - 2026 (USD Million)
      2. 5.7.2. The Middle-East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type, 2016 – 2026
        1. 5.7.2.1. The Middle-East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type, 2016 – 2026 (USD Million)
      3. 5.7.3. The Middle-East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Indication, 2016 – 2026
        1. 5.7.3.1. The Middle-East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Indication, 2016 – 2026 (USD Million)
      4. 5.7.4. The Middle-East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by End User, 2016 – 2026
        1. 5.7.4.1. The Middle-East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by End User, 2016 – 2026 (USD Million)
      5. 5.7.5. GCC Countries
        1. 5.7.5.1. GCC Countries B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      6. 5.7.6. South Africa
        1. 5.7.6.1. South Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      7. 5.7.7. Rest of Middle-East Africa
        1. 5.7.7.1. Rest of Middle-East Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
  6. Chapter 6 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market – Competitive Landscape
    1. 6.1. Competitor Market Share – Revenue
    2. 6.2. Market Concentration Rate Analysis, Top 3 and Top 5 Players
    3. 6.3. Strategic Developments
      1. 6.3.1. Acquisitions and Mergers
      2. 6.3.2. New Products
      3. 6.3.3. Research & Development Activities
  7. Chapter 7 Company Profiles
    1. 7.1. Sutro Biopharma
      1. 7.1.1. Company Overview
      2. 7.1.2. Product/Service Portfolio
      3. 7.1.3. Sutro Biopharma Sales, Revenue, and Gross Margin
      4. 7.1.4. Sutro Biopharma Revenue and Growth Rate
      5. 7.1.5. Sutro Biopharma Market Share
      6. 7.1.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    2. 7.2. Malin Corporation
      1. 7.2.1. Company Overview
      2. 7.2.2. Product/Service Portfolio
      3. 7.2.3. Malin Corporation Sales, Revenue, and Gross Margin
      4. 7.2.4. Malin Corporation Revenue and Growth Rate
      5. 7.2.5. Malin Corporation Market Share
      6. 7.2.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    3. 7.3. Eureka Therapeutics
      1. 7.3.1. Company Overview
      2. 7.3.2. Product/Service Portfolio
      3. 7.3.3. Eureka Therapeutics Sales, Revenue, and Gross Margin
      4. 7.3.4. Eureka Therapeutics Revenue and Growth Rate
      5. 7.3.5. Eureka Therapeutics Market Share
      6. 7.3.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    4. 7.4. Transposagen Biopharmaceuticals
      1. 7.4.1. Company Overview
      2. 7.4.2. Product/Service Portfolio
      3. 7.4.3. Transposagen Biopharmaceuticals Sales, Revenue, and Gross Margin
      4. 7.4.4. Transposagen Biopharmaceuticals Revenue and Growth Rate
      5. 7.4.5. Transposagen Biopharmaceuticals Market Share
      6. 7.4.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    5. 7.5. firstVentury Equity
      1. 7.5.1. Company Overview
      2. 7.5.2. Product/Service Portfolio
      3. 7.5.3. firstVentury Equity Sales, Revenue, and Gross Margin
      4. 7.5.4. firstVentury Equity Revenue and Growth Rate
      5. 7.5.5. firstVentury Equity Market Share
      6. 7.5.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    6. 7.6. Five Prime Therapeutics
      1. 7.6.1. Company Overview
      2. 7.6.2. Product/Service Portfolio
      3. 7.6.3. Five Prime Therapeutics Sales, Revenue, and Gross Margin
      4. 7.6.4. Five Prime Therapeutics Revenue and Growth Rate
      5. 7.6.5. Five Prime Therapeutics Market Share
      6. 7.6.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    7. 7.7. Bluebird Bio
      1. 7.7.1. Company Overview
      2. 7.7.2. Product/Service Portfolio
      3. 7.7.3. Bluebird Bio Sales, Revenue, and Gross Margin
      4. 7.7.4. Bluebird Bio Revenue and Growth Rate
      5. 7.7.5. Bluebird Bio Market Share
      6. 7.7.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    8. 7.8. Dana-Farber Cancer Institute
      1. 7.8.1. Company Overview
      2. 7.8.2. Product/Service Portfolio
      3. 7.8.3. Dana-Farber Cancer Institute Sales, Revenue, and Gross Margin
      4. 7.8.4. Dana-Farber Cancer Institute Revenue and Growth Rate
      5. 7.8.5. Dana-Farber Cancer Institute Market Share
      6. 7.8.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    9. 7.9. Deerfield Partners
      1. 7.9.1. Company Overview
      2. 7.9.2. Product/Service Portfolio
      3. 7.9.3. Deerfield Partners Sales, Revenue, and Gross Margin
      4. 7.9.4. Deerfield Partners Revenue and Growth Rate
      5. 7.9.5. Deerfield Partners Market Share
      6. 7.9.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    10. 7.10. Onyx Pharmaceuticals
      1. 7.10.1. Company Overview
      2. 7.10.2. Product/Service Portfolio
      3. 7.10.3. Onyx Pharmaceuticals Sales, Revenue, and Gross Margin
      4. 7.10.4. Onyx Pharmaceuticals Revenue and Growth Rate
      5. 7.10.5. Onyx Pharmaceuticals Market Share
      6. 7.10.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    11. 7.11. GlaxoSmithKline plc
      1. 7.11.1. Company Overview
      2. 7.11.2. Product/Service Portfolio
      3. 7.11.3. GlaxoSmithKline plc Sales, Revenue, and Gross Margin
      4. 7.11.4. GlaxoSmithKline plc Revenue and Growth Rate
      5. 7.11.5. GlaxoSmithKline plc Market Share
      6. 7.11.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    12. 7.12. Novartis AG
      1. 7.12.1. Company Overview
      2. 7.12.2. Product/Service Portfolio
      3. 7.12.3. Novartis AG Sales, Revenue, and Gross Margin
      4. 7.12.4. Novartis AG Revenue and Growth Rate
      5. 7.12.5. Novartis AG Market Share
      6. 7.12.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    13. 7.13. Gilead Sciences. Inc.
      1. 7.13.1. Company Overview
      2. 7.13.2. Product/Service Portfolio
      3. 7.13.3. Gilead Sciences. Inc. Sales, Revenue, and Gross Margin
      4. 7.13.4. Gilead Sciences. Inc. Revenue and Growth Rate
      5. 7.13.5. Gilead Sciences. Inc. Market Share
      6. 7.13.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    14. 7.14. Amgen Inc
      1. 7.14.1. Company Overview
      2. 7.14.2. Product/Service Portfolio
      3. 7.14.3. Amgen Inc Sales, Revenue, and Gross Margin
      4. 7.14.4. Amgen Inc Revenue and Growth Rate
      5. 7.14.5. Amgen Inc Market Share
      6. 7.14.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    15. 7.15. Affimed N.V,
      1. 7.15.1. Company Overview
      2. 7.15.2. Product/Service Portfolio
      3. 7.15.3. Affimed N.V, Sales, Revenue, and Gross Margin
      4. 7.15.4. Affimed N.V, Revenue and Growth Rate
      5. 7.15.5. Affimed N.V, Market Share
      6. 7.15.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    16. 7.16. Autolus Ltd.
      1. 7.16.1. Company Overview
      2. 7.16.2. Product/Service Portfolio
      3. 7.16.3. Autolus Ltd. Sales, Revenue, and Gross Margin
      4. 7.16.4. Autolus Ltd. Revenue and Growth Rate
      5. 7.16.5. Autolus Ltd. Market Share
      6. 7.16.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    17. 7.17. Juno Therapeutics
      1. 7.17.1. Company Overview
      2. 7.17.2. Product/Service Portfolio
      3. 7.17.3. Juno Therapeutics Sales, Revenue, and Gross Margin
      4. 7.17.4. Juno Therapeutics Revenue and Growth Rate
      5. 7.17.5. Juno Therapeutics Market Share
      6. 7.17.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    18. 7.18. Celgene Corporation
      1. 7.18.1. Company Overview
      2. 7.18.2. Product/Service Portfolio
      3. 7.18.3. Celgene Corporation Sales, Revenue, and Gross Margin
      4. 7.18.4. Celgene Corporation Revenue and Growth Rate
      5. 7.18.5. Celgene Corporation Market Share
      6. 7.18.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    19. 7.19. Poseida Therapeutics, Inc
      1. 7.19.1. Company Overview
      2. 7.19.2. Product/Service Portfolio
      3. 7.19.3. Poseida Therapeutics, Inc Sales, Revenue, and Gross Margin
      4. 7.19.4. Poseida Therapeutics, Inc Revenue and Growth Rate
      5. 7.19.5. Poseida Therapeutics, Inc Market Share
      6. 7.19.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
  8. Chapter 8 B-Cell Maturation Antigen (BCMA) Targeted Therapies — Industry Analysis
    1. 8.1. Introduction and Taxonomy
    2. 8.2. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market – Key Trends
      1. 8.2.1. Market Drivers
      2. 8.2.2. Market Restraints
      3. 8.2.3. Market Opportunities
    3. 8.3. Value Chain Analysis
    4. 8.4. Key Mandates and Regulations
    5. 8.5. Technology Roadmap and Timeline
    6. 8.6. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market – Attractiveness Analysis
      1. 8.6.1. By Product Type
      2. 8.6.2. By Indication
      3. 8.6.3. By End User
      4. 8.6.4. By Region
  9. Chapter 9 Industrial Chain, Sourcing Strategy, and Downstream Buyers
    1. 9.1. B-Cell Maturation Antigen (BCMA) Targeted Therapies Industrial Chain Analysis
    2. 9.2. Downstream Buyers
    3. 9.3. Distributors/Traders List
  10. Chapter 10 Marketing Strategy Analysis
    1. 10.1. Marketing Channel
    2. 10.2. Direct Marketing
    3. 10.3. Indirect Marketing
    4. 10.4. Marketing Channel Development Trends
    5. 10.5. Economic/Political Environmental Change
  11. Chapter 11 Report Conclusion & Key Insights
    1. 11.1. Key Insights from Primary Interviews & Surveys Respondents
    2. 11.2. Key Takeaways from Analysts, Consultants, and Industry Leaders
  12. Chapter 12 Research Approach & Methodology
    1. 12.1. Report Description
    2. 12.2. Research Scope
    3. 12.3. Research Methodology
      1. 12.3.1. Secondary Research
      2. 12.3.2. Primary Research
      3. 12.3.3. Statistical Models
        1. 12.3.3.1. Company Share Analysis Model
        2. 12.3.3.2. Revenue Based Modeling
      4. 12.3.4. Research Limitations

      List of Figures

      Fig.1	Product Picture of B-Cell Maturation Antigen (BCMA) Targeted Therapies
      Fig.2	Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.3	Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Absolute Revenue Opportunity, 2016 – 2026 (USD Million)
      Fig.4	Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Incremental Revenue Opportunity, 2020 – 2026 (USD Million)
      Fig.5	COVID-19 Impacts on BCMA Targeted Therapies Market
      Fig.6	COVID-19 Impact on the Players
      Fig.7	Business Strategies and Recommendations
      Fig.8	Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share, by Product Type, 2020 & 2026 (USD Million)
      Fig.9	Global CAR-T Cell B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.10	Global Antibody Drug Conjugates B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.11	Global Bispecific Antibodies B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.12	Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share, by Indication, 2020 & 2026 (USD Million)
      Fig.13	Global Multiple Myeloma B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.14	Global Acute Lymphoblastic Leukemia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.15	Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share, by End User, 2020 & 2026 (USD Million)
      Fig.16	Global Hospitals B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.17	Global Cancer Research Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.18	Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share, by Region, 2020 & 2026 (USD Million)
      Fig.19	North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.20	U.S. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.21	Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.22	Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.23	Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.24	France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.25	U.K. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.26	Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.27	Spain B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.28	Rest of Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.29	Asia Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.30	China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.31	Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.32	India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.33	South  Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.34	South-East Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.35	Rest of Asia Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.36	Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.37	Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.38	Mexico B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.39	Rest of Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.40	The Middle-East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.41	GCC Countries B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.42	South Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.43	Rest of Middle-East Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2016 – 2026 (USD Million)
      Fig.44	Competitor Market Share – Revenue
      Fig.45	Sutro Biopharma Revenue and Growth Rate
      Fig.46	Sutro Biopharma Market Share
      Fig.47	Malin Corporation Revenue and Growth Rate
      Fig.48	Malin Corporation Market Share
      Fig.49	Eureka Therapeutics Revenue and Growth Rate
      Fig.50	Eureka Therapeutics Market Share
      Fig.51	Transposagen Biopharmaceuticals Revenue and Growth Rate
      Fig.52	Transposagen Biopharmaceuticals Market Share
      Fig.53	firstVentury Equity Revenue and Growth Rate
      Fig.54	firstVentury Equity Market Share
      Fig.55	Five Prime Therapeutics Revenue and Growth Rate
      Fig.56	Five Prime Therapeutics Market Share
      Fig.57	Bluebird Bio Revenue and Growth Rate
      Fig.58	Bluebird Bio Market Share
      Fig.59	Dana-Farber Cancer Institute Revenue and Growth Rate
      Fig.60	Dana-Farber Cancer Institute Market Share
      Fig.61	Deerfield Partners Revenue and Growth Rate
      Fig.62	Deerfield Partners Market Share
      Fig.63	Onyx Pharmaceuticals Revenue and Growth Rate
      Fig.64	Onyx Pharmaceuticals Market Share
      Fig.65	GlaxoSmithKline plc Revenue and Growth Rate
      Fig.66	GlaxoSmithKline plc Market Share
      Fig.67	Novartis AG Revenue and Growth Rate
      Fig.68	Novartis AG Market Share
      Fig.69	Gilead Sciences. Inc. Revenue and Growth Rate
      Fig.70	Gilead Sciences. Inc. Market Share
      Fig.71	Amgen Inc Revenue and Growth Rate
      Fig.72	Amgen Inc Market Share
      Fig.73	Affimed N.V, Revenue and Growth Rate
      Fig.74	Affimed N.V, Market Share
      Fig.75	Autolus Ltd. Revenue and Growth Rate
      Fig.76	Autolus Ltd. Market Share
      Fig.77	Juno Therapeutics Revenue and Growth Rate
      Fig.78	Juno Therapeutics Market Share
      Fig.79	Celgene Corporation Revenue and Growth Rate
      Fig.80	Celgene Corporation Market Share
      Fig.81	Poseida Therapeutics, Inc Revenue and Growth Rate
      Fig.82	Poseida Therapeutics, Inc Market Share
      Fig.83	Market Dynamics
      Fig.84	Global B-Cell Maturation Antigen (BCMA) Targeted Therapies – Value Chain Analysis
      Fig.85	Key Mandates and Regulations
      Fig.86	Technology Roadmap and Timeline
      Fig.87	Market Attractiveness Analysis – By Product Type
      Fig.88	Market Attractiveness Analysis – By Indication
      Fig.89	Market Attractiveness Analysis – By End User
      Fig.90	Market Attractiveness Analysis – By Region
      Fig.91	B-Cell Maturation Antigen (BCMA) Targeted Therapies Industrial Chain Analysis
      Fig.92	Market Channels
      Fig.93	Marketing Channel Development Trend
      Fig.94	Growth in World Gross Product, 2008-2018
      

      List of Tables

      Table 1	Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, 2020 & 2026 (USD Million)
      Table 2	Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type, 2016 – 2026 (USD Million)
      Table 3	Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Indication, 2016 – 2026 (USD Million)
      Table 4	Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by End User, 2016 – 2026 (USD Million)
      Table 5	Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Region, 2016 – 2026 (USD Million)
      Table 6	North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Country, 2016 – 2026 (USD Million)
      Table 7	North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type, 2016 – 2026 (USD Million)
      Table 8	North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Indication, 2016 – 2026 (USD Million)
      Table 9 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by End User, 2016 – 2026 (USD Million)
      Table 10 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Country, 2016 – 2026 (USD Million)
      Table 11 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type, 2016 – 2026 (USD Million)
      Table 12 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Indication, 2016 – 2026 (USD Million)
      Table 13 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by End User, 2016 – 2026 (USD Million)
      Table 14 Asia Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Country, 2016 – 2026 (USD Million)
      Table 15 Asia Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type, 2016 – 2026 (USD Million)
      Table 16 Asia Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Indication, 2016 – 2026 (USD Million)
      Table 17 Asia Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by End User, 2016 – 2026 (USD Million)
      Table 18 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Country, 2016 – 2026 (USD Million)
      Table 19 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type, 2016 – 2026 (USD Million)
      Table 20 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Indication, 2016 – 2026 (USD Million)
      Table 21 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by End User, 2016 – 2026 (USD Million)
      Table 22 The Middle-East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Country, 2016 – 2026 (USD Million)
      Table 23 The Middle-East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type, 2016 – 2026 (USD Million)
      Table 24 The Middle-East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Indication, 2016 – 2026 (USD Million)
      Table 25 The Middle-East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by End User, 2016 – 2026 (USD Million)
      Table 26 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market - Company Revenue Analysis, 2016 – 2020 (USD Million)
      Table 27 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market - Company Revenue Share Analysis, 2016 – 2020 (%)
      Table 28 Acquisitions and Mergers
      Table 29 Market Drivers – Impact Analysis
      Table 30 Market Restraints
      Table 31 Market Opportunities
      Table 32 Major Buyers of B-Cell Maturation Antigen (BCMA) Targeted Therapies
      Table 33 Distributors/Traders of B-Cell Maturation Antigen (BCMA) Targeted Therapies by Region
      

Industry Major Market Players

  • Poseida Therapeutics Inc.
  • Autolus Ltd.
  • Juno Therapeutics
  • Malin Corporation
  • Eureka Therapeutics
  • Transposagen Biopharmaceuticals
  • Sutro Biopharma
  • Onyx Pharmaceuticals
  • GlaxoSmithKline plc
  • Novartis AG
  • Gilead Sciences. Inc.
  • Amgen Inc.
  • Affimed N.V
  • firstVentury Equity
  • Five Prime Therapeutics
  • Bluebird Bio
  • Deerfield Partners
  • Celgene Corporation
  • Dana-Farber Cancer Institute others.

Safe and Secure SSL Encrypted

Choose License Type

Inquiry For Buying

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

have a question

HAVE A QUESTION? Executive will help you find what you are looking for.


REQUEST CUSTOMIZATION

Still haven't found what you're looking for? Speak to our Custom Research Team

Learn More
Facts & Factors provides an array of marketing and business research solutions distinctly designed by our expertise for the clients.
Copyright © 2021 Facts & Factors. All Rights Reserved. Sitemap - Privacy Policy - Terms & Conditions